This trial is testing whether giving stereotactic radiosurgery at the same time as immune checkpoint inhibitor therapy is better than giving immune checkpoint inhibitor therapy alone in patients with non-small cell lung cancer that has spread to the brain.
1 Primary · 4 Secondary · Reporting Duration: from randomization through study completion, an average of 3 years
80 Total Participants · 2 Treatment Groups
Primary Treatment: Stereotactic Radiosurgery · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: